Access & Savings information
YOUR PATIENTS CAN SAVE TODAY ON THEIR VTAMA CREAM PRESCRIPTION

Eligible commercially insured patients may pay as little as $0.* Commercially insured patients may pay as little as $75.

*Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.
MYVTAMA SAVINGS
*Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.
ADDITIONAL RESOURCES
brochure
brochurePatient brochure

This brochure is a quick and concise guide to VTAMA cream. Inside, your patients will find helpful information around safety, results, and before-and-after photos.

guide
guideDoctor Discussion Guide

This short assessment will help your patients find a treatment that’s right for them. It may be best for them to fill out and use as a guide for any questions they have during their appointment with you.

FAQs

VTAMA cream is a once-daily, non-steroidal topical treatment for adults with plaque psoriasis. It is a first-in-class topical Aryl hydrocarbon Receptor (AhR) agonist that was approved by the FDA in May 2022.2,9

AhR is a ligand-dependent transcription factor that is naturally present in skin cells.
Activation of AhR by tapinarof helps2:
  • Decrease Th17 cytokines (IL-17A and IL-17F)12
  • Increase antioxidant activity via the Nrf2 pathway19
  • Increase skin barrier proteins filaggrin, involucrin, and loricrin2,12,18
  • Decrease Th2 cytokines (IL-4, IL-5, IL-13)20,21
You can learn more about AhR by watching the Mechanism of Disease video.

VTAMA cream has been studied in 2 identical pivotal studies as well as an open-label, long-term extension study.1,3

The pivotal studies (PSOARING 1 and PSOARING 2) were double-blinded and vehicle-controlled, with more than 1000 patients with mild, moderate, or severe psoriasis.1

The open-label, long-term extension study (PSOARING 3) was designed to evaluate the safety, efficacy, tolerability, durability of response, and duration of effect (median time to first worsening) over 40 weeks.3

You can learn more about the efficacy of VTAMA cream here.

In clinical studies, the most common adverse reactions (occurring in ≥1% of patients in both pivotal 12-week studies) were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. Adverse reactions leading to treatment discontinuation in >1% of subjects who received VTAMA cream were contact dermatitis (2.9%) and folliculitis (2.8%).1

In a 40-week, long-term, open-label extension study, the safety profile of VTAMA cream was consistent with what was seen in the pivotal studies.11

You can learn more about the safety profile of VTAMA cream here.

VTAMA cream is a non-steroidal topical treatment indicated for adults with plaque psoriasis. It has been approved for use in adult patients with mild, moderate, and severe plaque psoriasis.1,9

Want to learn more about what type of patients can be prescribed VTAMA cream? Check out our patient profiles.

VTAMA cream is a versatile and well-tolerated treatment option for adult plaque psoriasis with no restrictions on topical external use to affected areas. It can even be used on typically sensitive areas, including the face, neck, axillae, intertriginous areas, inframammary areas, genitalia, and anal crux. VTAMA cream is not for oral, ophthalmic, or intravaginal use.1,4

Learn more about tolerability of VTAMA cream here.

A thin layer of VTAMA cream should be applied to only the affected areas once daily. Avoid applying VTAMA cream to unaffected areas of skin.1

After applying VTAMA cream, patients should wash their hands (unless the affected area is on the hands). If someone else helps apply it, they should wash their hands when finished.1

VTAMA cream is not for oral, ophthalmic, or intravaginal use.1

VTAMA cream was not studied in patients who were pregnant or breastfeeding. There are insufficient data available to evaluate drug-associated risks of major birth defects, miscarriage, or other maternal or fetal outcomes. No data are available regarding the presence of tapinarof in human milk or the effects of tapinarof on breastfed infants or on milk production.1 However, tapinarof was detected in rat offspring following subcutaneous administration to pregnant female rats, which suggests that tapinarof was transferred into the milk of lactating rats.

VTAMA cream should be stored at 20 °C to 25 °C (68 °F to 77 °F), with excursions permitted between 15 °C and 30 °C (59 °F and 86 °F).1 VTAMA cream should be kept out of reach of children.

It should not be frozen or exposed to excessive heat.1

Dermavant is committed to making our medications accessible and affordable to adult patients with plaque psoriasis. With the MyVTAMA Savings Card, eligible commercially insured patients may pay as little as $0* for VTAMA cream. Commercially insured patients may pay as little as $75.

Additional resources, including the Patient Brochure, and instructional videos, are available to help patients get the most of their treatment.

*Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.